Validation of quantitative intraoperative transesophageal echocardiography

Transesophageal echocardiography (TEE) is a new monitoring technique that images the heart and provides information on regional wall motion and left ventricular filling. However, despite its potential for inaccuracy due to its retrocardiac position and angulation, TEE has not been validated by another imaging technique. Using direct on-heart echocardiography (OHE) as a standard, the authors evaluated the ability of TEE to measure accurately left ventricular end-diastolic area (EDa), end-systolic area (ESa), and ejection fraction area (EFa). Ten patients with coronary artery disease without evidence of valvular dysfunction undergoing myocardial revascularization were studied. A Diasonics 3.5 MHz two-dimensional TEE probe was introduced into each patient's esophagus and positioned to obtain a view equivalent to the parasternal short-axis projection. A similar view was obtained by OHE using a sterilely prepared 3 MHz ATL probe placed on either the pericardium or epicardium. In each patient, immediately prior to and after pericardiotomy, both transesophageal and on-heart short-axis views at the level of the papillary muscles were obtained. Using a dedicated Diasonics computer echoanalyzer, EDa and ESa from four consecutive cardiac cycles were outlined with a light pen and averaged. EFa was calculated by the formula EFa = (EDa - ESa)/EDa. Seventeen comparable transesophageal and on-heart echocardiograms were obtained. ESa by TEE correlated well with ESa by OHE (15.13 +/- 9.62 cm2 vs. 14.92 +/- 10.53 cm2; r = 0.94). Similar results were obtained for EDa (27.75 +/- 9.88 cm2 vs. 30.40 +/- 13.99 cm2; r = 0.88) and EFa (0.49 +/- 0.17 vs. 0.54 +/- 0.13; r = 0.92). filling and ejection.

The effect of temperature, mean arterial pressure, and cardiopulmonary bypass flows on somatosensory evoked potential latency in man

Median nerve somatosensory evoked potentials were recorded in 21 patients undergoing cardiac surgical procedures utilizing cardiopulmonary bypass, in order to establish the effects of hypothermia, reductions in mean arterial pressure, and alterations in cardiopulmonary bypass flows on evoked potential latency. Induction and maintenance of anesthesia with fentanyl caused a significant prolongation of latency of the first cortical peak. Temperature changes were linearly correlated with changes in latency for peaks recorded from Erb's point (r = -0.843, p less than 0.01) and the contralateral cortex (r = 0.843, p less than 0.01). There was no significant effect of mean arterial pressure or cardiopulmonary bypass flow reductions on latencies under the conditions of this study. Our results emphasize the importance of monitoring peripheral and first cortical peak latencies in evaluating somatosensory evoked potentials. It is suggested that peak latency prolongations beyond those predicted by temperature alterations may be indicative of hypoperfusion.

The safety and efficacy of esmolol during myocardial revascularization

The safety and efficacy of esmolol during high-dose fentanyl anesthesia were studied in 37 patients undergoing coronary artery bypass grafting (CABG). The anesthetic management consisted of fentanyl 75 micrograms/kg, pancuronium 0.15 mg/kg, and O2. To assess the safety of esmolol, it was administered in a double-blind manner to 17 anesthetized patients prior to surgical incision. Infusion of the drug was increased in stepwise fashion to obtain administration rates between 100 and 300 micrograms X kg-1 X min-1. Esmolol produced small but significant increases in pulmonary capillary wedge pressure (PCWP) (8.3 +/- 1.7 to 13.2 +/- 2.0 mmHg) when compared with placebo (10.9 +/- 1.0 to 12.1 +/- 0.6 mmHg) (P less than 0.05). For the other studied parameters (heart rate, mean arterial pressure, central venous pressure, cardiac index, stroke index, left ventricular stroke work index, systemic vascular resistance, and peripheral vascular resistance), no significant differences were observed between esmolol and placebo. To evaluate the efficacy of esmolol, 20 patients were randomly assigned to an esmolol group (n = 11) or a placebo group (n = 9). The study medication was infused from 5 min before induction through initiation of cardiopulmonary bypass. Infusion of esmolol at 200 micrograms X kg-1 X min-1 prevented tachycardia in response to intubation. In the esmolol group the heart rate increased from 63.4 +/- 2.7 to 67.6 +/- 2.9 beats/min after intubation, while in the placebo group it increased from 61.4 +/- 4.3 to 72.4 +/- 3.4 beats/min (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Verapamil and myocardial preservation in patients undergoing coronary artery bypass surgery

The value of verapamil hydrochloride as a myocardial preservative when administered prior to or during periods of myocardial ischemia was studied in patients with normal preoperative cardiac function during elective coronary artery bypass grafting. Myocardial protection included systemic hypothermia (28 degrees C) and hypothermic hyperkalemic cardioplegia. Patients were randomly divided into four groups. Group 1 received intravenous administration of verapamil prior to aortic cross-clamping. Group 2 received intravenous verapamil plus verapamil in the cardioplegic solution. Group 3 received verapamil in the cardioplegic solution only. Group 4 was given no verapamil. Oxygen extraction during the reperfusion period was greatest in Group 4. However, the incidence of pacing was 50 to 78% in Groups 2 and 3, who were given verapamil in the cardioplegic solution. These groups also had a greater need for inotropic agents for discontinuation of cardiopulmonary bypass (CPB). This study indicates that verapamil may be a useful pretreatment prior to CPB and ischemia, but is not effective and may even be detrimental when administered during ischemic periods to patients with good myocardial function.

The role of isosorbide dinitrate in the treatment of perioperative hypertension

Intravenous nitroglycerin (NTG) has recently been found to be useful for the control of blood pressure during the perioperative period, especially during coronary artery bypass procedures. The objective of this study was to determine whether intravenous isosorbide dinitrate (ISDN) could play a similar role. Sixty-seven patients undergoing coronary artery bypass grafting at three centers were randomly assigned to an ISDN or NTG treatment group. The hemodynamic performance of all patients was assessed by the methods commonly used for cardiac patients (ECG, arterial line, thermodilution pulmonary artery catheter). One of the two nitrates was infused whenever the systolic blood pressure or the pulmonary capillary wedge pressure exceeded predetermined values. Treatment by either agent was considered successful if the elevated values returned to normal. NTG reduced the blood pressure in a higher percentage of hypertensive events. The rates of success were 84% for NTG vs 72% for ISDN in the prebypass phase, 93% vs 64% in the postbypass phase, and 71% vs 54% in the postoperative phase. Increased ISDN effectiveness may be attained with the use of a bolus administration before continuous infusion or with the use of a rapid rate of infusion.

High-dose hydromorphone (Dilaudid) for coronary artery bypass surgery

The hemodynamic effects of high-dose hydromorphone hydrochloride (H), 1.25 mg/kg, were investigated in 10 patients with normal ventricular function undergoing coronary artery bypass graft (CABG) surgery. One patient with unstable angina was excluded from the study because of hypotension and facial flushing after a 6-mg test dose of H. Nine patients showed no significant change in heart rate (HR), mean arterial pressure (MAP), cardiac index (CI), left ventricular stroke work index (LVSWI), systemic vascular resistance (SVR), pulmonary capillary wedge pressure (PCWP), or coronary perfusion pressure (CPP) after H; central venous pressure (CVP) increased significantly (P less than 0.05). Loss of consciousness did not occur reliably after H. The addition of 50% N2O to H produced significant decreases in CI and LVSWI (P less than 0.05). Hemodynamic responses to tracheal intubation, skin incision, and sternotomy included depression of CI, elevation of SVR, and increased MAP (P less than 0.05). Vasodilators were required in eight patients before aortic cannulation and after extracorporeal circulation. Mean time to awakening was 7.6 hr after the full dose of H, and extubation was performed the morning after surgery (21 hr after H) according to our usual practice. We conclude that very large doses of H (equivalent in analgesic terms to 10 mg/kg of morphine sulfate) are well tolerated by most patients undergoing CABG surgery, but unconsciousness and complete suppression of sympathetic responses require supplementation of H with additional anesthetic agents or vasodilators.

Non-cardiac surgery in patients with prior myocardial revascularization

Patients who had undergone aorto-coronary bypass grafts (ACBG) were assessed for the incidence of cardiac complications in the postoperative period following subsequent non-cardiac surgery. One hundred and twenty-one patients had 13 complications (11 per cent). A significantly higher risk of cardiac complications (27 per cent) was found in patients undergoing non-cardiac procedures in the first month after ACBG. This remained higher (17 per cent) until the sixth month following ACBG. Significant factors which increased the risk of cardiac complications in the postoperative period included preoperative congestive heart failure (33 per cent), cardiac risk index score classification of III or IV (37 per cent), surgery on major vessels, and surgery necessitated because of a complication of the ACBG itself (17 per cent). No correlation was found between cardiac complication rates and recurrent angina, hypertension, the use of beta-blockers or digoxin, or anaesthetic technique. It is suggested that all but emergency surgery should be postponed in the first month following ACBG, and elective surgery be delayed for up to six months.

Nitroglycerin as an adjunct to hypothermic hyperkalemic cardioplegia

The efficacy of nitroglycerin as an adjunct to hyperkalemic hypothermic cardioplegia was assessed by measurement of changes in coronary vascular resistance. Thirty patients undergoing coronary artery bypass grafting were studied. During a 1000 ml infusion of cardioplegia, a bolus of 1 mg of nitroglycerin or control solution was injected while the infusion rate was kept constant. Measurement of aortic root pressure allowed calculation of coronary vascular resistance. There was a mean decrease of 21.2% in coronary vascular resistance after a bolus of 1 mg of nitroglycerin was injected in the study group (p less than .001, n = 15); there was no significant change in resistance in the control group. There was also no significant change in systemic vascular resistance in either group. A retrospective blind analysis of the anatomic angiographic features of the heart with a quantitative assessment of both coronary stenoses and coronary collaterals was made. There was no correlation between coronary scores and preinjection coronary vascular resistance. There was also no correlation between collateral scores and the change in coronary vascular resistance with nitroglycerin. These results suggest that nitroglycerin is an effective coronary vasodilator when used as an adjunct in hypothermic hyperkalemic cardioplegia and that baseline coronary vascular resistance or change in coronary vascular resistance with nitroglycerin cannot be predicted on the basis of current assessments of coronary angiograms.

Cardiovascular responses to verapamil during coronary artery bypass graft surgery

The cardiovascular effects of verapamil administration during coronary artery bypass graft surgery were studied in patients with normal left ventricular function. Anesthesia consisted of morphine, diazepam, and nitrous oxide. Before atrial cannulation for cardiopulmonary bypass, 16 patients received either verapamil (N = 8) 0.075 mg X kg-1 or an equal volume of its solvent (N = 8) administered intravenous over 1 min. Hemodynamic functions and serum verapamil levels were measured over the succeeding 10 min. Verapamil produced rapid reductions in systemic vascular resistance, systemic arterial blood pressure, and left ventricular stroke work index. The PR interval increased slightly and two of the patients who had a baseline PR interval of 200 msec developed a mild first degree heart block. Heart rate, cardiac index, pulmonary capillary wedge pressure, central venous pressure, and right ventricular stroke work index did not significantly change. No measured cardiovascular functions changed in the control group. Serum verapamil levels peaked at 346.4 +/- 143.5 ng X ml-1 0.5 min after drug administration and then rapidly declined. Both groups of patients tolerated surgery and the immediate postoperative recovery period without hemodynamic compromise. Verapamil can be safely administered before cardiopulmonary bypass in patient with good left ventricular function during narcotic-based anesthesia.

Hemodynamic interactions of verapamil and isoflurane

The hemodynamic interactions of verapamil and isoflurane were studied in eight dogs. Left ventricular function was analyzed using a right heart bypass preparation to permit rigid hemodynamic control. Hemodynamic studies were performed at 0.7, 1.05, and 1.40% isoflurane before and during the maintenance of two stable levels of verapamil, administered intravenously by combining a bolus dose (0.2 mg X kg-1) with an infusion (3.0 and 6.0 micrograms X kg-1 X min-1). Isoflurane produced a concentration-dependent depression of left ventricular function as indicated by dP/dt max, per cent systolic shortening, and left ventricular function curves. This depression was enhanced in a dose-plasma concentration-dependent manner by verapamil and was reversed by calcium chloride. Isoflurane alone and the combination of verapamil and isoflurane decreased systemic vascular resistance in a dose-dependent fashion that was antagonized partially by calcium chloride. Therefore, verapamil can enhance the hemodynamic effects of isoflurane in a dose-related manner that needs to be considered when both drugs are administered together.

Pretreatment with lidoflazine, a calcium-channel blocker. Useful adjunct to heterogeneous cold potassium cardioplegia

Ten mongrel dogs were studied to determine if pretreatment with lidoflazine would protect the canine myocardium during aortic cross-clamping when circumflex coronary artery occlusion limits the distribution of cold potassium cardioplegia. A canine right heart bypass preparation was used. Regional function was determined with a sonomicrometer. Twenty minutes before aortic cross-clamping, lidoflazine or solvent was administered in a random, blind fashion. A circumflex artery snare prevented the cardioplegic solution from entering the circumflex artery. A 100 minute arrest period with cardioplegic infusion every 20 minutes was followed by 45 minutes of reperfusion before global and regional function were reevaluated. In the group receiving solvent, postarrest function in the circumflex region recovered to only 30% of prearrest values (p less than 0.05), a marked functional deterioration. In the group protected by lidoflazine, function in the circumflex region returned to 90% of prearrest values (NS). Function in the left anterior descending (LAD) regions of both groups demonstrated full recovery after arrest. Global left ventricular function was well preserved in both groups and failed to reflect the damaged, malfunctioning region in the group receiving solvent. These findings suggest that pretreatment with lidoflazine can improve myocardial protection when delivery of cardioplegia is not homogeneous.

Myxoedema and open heart surgery: anaesthesia and intensive care unit experience

Myxoedema has been considered a major anaesthetic risk which could be increased by concurrent heart disease. Thyroid ablation with the production of myxoedema has, in the past, been used to control intractable angina. Eight ablated patients (Group I) and five patients with heart disease and incidental hypothyroidism (Group II) presented for open heart surgery. Management included diazepam-narcotic anaesthesia in generally reduced doses, careful monitoring and the use of digoxin, steroids and I-thyroxin given during or after operation. All patients survived. A number of the anaesthetic considerations and potential problems with myxoedema are discussed.

Esophageal lead for intraoperative electrocardiographic monitoring

The use and safety of the esophageal electrocardiogram for detection and diagnosis of dysrhythmias or ischemia during anesthesia was compared with the conventional electrocardiogram using leads II and V5 in 20 patients undergoing coronary artery bypass graft surgery. Using an intra-atrial electrocardiogram as the standard to provide detection and definitive diagnosis of dysrhythmias, the correct diagnosis from leads II and V5 was made in 53.8% and 42.3% of cases, respectively, whereas 100% of the dysrhythmias were properly diagnosed from the esophageal electrocardiogram (p less than 0.05). In two patients, the presence of a significant dysrhythmia was not detected using standard leads II and V5 alone. Large, distinct P waves, resulting from the proximity of the esophageal lead to the left atrium, clearly established the temporal relationship between atrial and ventricular depolarization. Posterior myocardial ischemia was diagnosed in one patient by ST-segment elevation in the esophageal electrocardiogram, whereas leads II and V5 did not demonstrate ischemic changes. No complications were encountered during the study. The esophageal lead is safe, simple to use, and provides valuable information for detection or diagnosis of dysrhythmias and myocardial ischemia during anesthesia.